AR042042A1 - Administracion combinada de una indolinona con un agente quimioterapeutico para trastornos de proliferacion celular - Google Patents
Administracion combinada de una indolinona con un agente quimioterapeutico para trastornos de proliferacion celularInfo
- Publication number
- AR042042A1 AR042042A1 ARP030104194A ARP030104194A AR042042A1 AR 042042 A1 AR042042 A1 AR 042042A1 AR P030104194 A ARP030104194 A AR P030104194A AR P030104194 A ARP030104194 A AR P030104194A AR 042042 A1 AR042042 A1 AR 042042A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- heteroaryl
- aryl
- cycloalkyl
- independently
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
Abstract
La presente se refiere a un método de tratamiento del cáncer mediante la administración de una combinación de un compuesto de indolinona con otro agente quimioterapéutico. La combinación de un compuesto de indolinona de fórmula (1), con otro agente quimioterapéutico provee un efecto potenciado en tratamiento del pacientes con cáncer. Reivindicación 1: El uso de un compuesto de fórmula (1) y por lo menos un agente quimioterapéutico para el tratamiento del cáncer, en el cual: cada R es, en forma independiente, hidrógeno, hidroxi, alquilo, arilo, cicloalquilo, heteroarilo, alcoxi, heterocíclico o amino; cada R1 es, en forma independiente, alquilo, halo, alcoxi, haloalquilo, haloalcoxi, cicloalquilo, heterocíclico, hidroxi, -C(O)-R8, -NR9R10, -NR9C(O)-R121 o -C(O)NR9R10; cada R2 es, en forma independiente, alquilo, arilo, heteroarilo, -C(O)-R8 o SO2R'', donde R'' es alquilo, arilo, heteroarilo, NR9N10 o alcoxi; cada R5 es, en forma independiente, hidrógeno, alquilo, arilo, haloalquilo, cicloalquilo, heteroarilo, heterociclo, hidroxi, -C(O)-R8 o (CHR)rR11; X es O, o S; j es 0 ó 1; p es 0, 1, 2 ó 3; q es 0, 1 ó 2; r es 0, 1, 2 ó 3; R8 es hidroxi, alquilo, arilo, heteroarilo, alcoxi, cicloalquilo o heterocíclico; R9 y R10 son, en forma independiente, hidrógeno, alquilo, arilo, aminoalquilo, heteroarilo, cicloalquilo y heterocíclico, o R9 y R10 junto con N pueden formar un anillo, donde los átomos del anillo se seleccionan del grupo formado por C, N, O y S; R11 es hidroxi, amino, amino monosustituido, amino disustituido, alquilo, arilo, heteroarilo, alcoxi, cicloalquilo o heterocíclico; R12 es alquilo, arilo, heteroarilo, alcoxi, cicloalquilo o heterocíclico; y Z es hidroxi, -O-alquilo, o -NR3R4, donde R3 y R4 son, en forma independiente, hidrógeno, alquilo, arilo, heteroarilo, cicloalquilo, o heterocíclico, o R3 y R4 pueden combinarse con N para formar un anillo donde los átomos del anillo se seleccionan del grupo formado por CH2, N, O y S, o resto de fórmula (2), en el cual Y es, en forma independiente, CH2, O, N o S, Q es C o N, n es, en forma independiente, 0, 1, 2, 3 ó 4, y m es 0, 1, 2 ó 3; o sus sales, hidratos, o solvatos aceptables para uso farmacéutico, y dicho por lo menos un agente quimioterapéutico se selecciona del grupo formado por agentes de interferencia de microtúbulos, inhibidores de topoisomerasa, agentes de alquilación, inhibidores de timidilato sintasa, activadores esteroidales irreversibles de aromatasa, anti-metabolitos, antagonistas de pirimidina, antagonistas de purina, inhibidores de la reductasa ribonucleotídica, e inhibidores de quinasa. Reivindicación 9: El uso como se reivindica en la reivindicación 1, en el cual el compuesto de fórmula (1) es: o una de sus sales, uno de sus solvatos o hidratos aceptables para uso
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US42638602P | 2002-11-15 | 2002-11-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR042042A1 true AR042042A1 (es) | 2005-06-08 |
Family
ID=32326343
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP030104194A AR042042A1 (es) | 2002-11-15 | 2003-11-13 | Administracion combinada de una indolinona con un agente quimioterapeutico para trastornos de proliferacion celular |
Country Status (22)
Country | Link |
---|---|
US (1) | US20040152759A1 (es) |
EP (1) | EP1562600A4 (es) |
JP (1) | JP2006508981A (es) |
KR (1) | KR20050086594A (es) |
CN (2) | CN101259131A (es) |
AR (1) | AR042042A1 (es) |
AU (1) | AU2003290943A1 (es) |
BR (1) | BR0315630A (es) |
CA (1) | CA2506308A1 (es) |
CO (1) | CO5700778A2 (es) |
GT (1) | GT200300245A (es) |
MX (1) | MXPA05005150A (es) |
NL (1) | NL1024779C2 (es) |
NO (1) | NO20052578L (es) |
PA (1) | PA8588601A1 (es) |
PE (1) | PE20040835A1 (es) |
PL (1) | PL376954A1 (es) |
RU (1) | RU2342140C2 (es) |
TW (1) | TW200418837A (es) |
UY (1) | UY28081A1 (es) |
WO (1) | WO2004045523A2 (es) |
ZA (1) | ZA200503841B (es) |
Families Citing this family (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ525324A (en) * | 2000-10-20 | 2005-03-24 | Eisai Co Ltd | Nitrogenous aromatic ring compounds |
ATE508747T1 (de) | 2003-03-10 | 2011-05-15 | Eisai R&D Man Co Ltd | C-kit kinase-hemmer |
CN101337930B (zh) | 2003-11-11 | 2010-09-08 | 卫材R&D管理有限公司 | 脲衍生物的制备方法 |
AU2005333515B2 (en) * | 2004-07-09 | 2012-05-10 | Arizona Board Of Regents, Acting On Behalf Of The University Of Arizona | Wortmannin analogs and methods of using same in combination with chemotherapeutic agents |
AU2005283422C1 (en) | 2004-09-17 | 2017-02-02 | Eisai R & D Management Co., Ltd. | Medicinal composition |
US20090117197A1 (en) * | 2005-03-21 | 2009-05-07 | Vicus Therapeutics Llc | Compositions and methods for ameliorating cachexia |
RU2007135167A (ru) * | 2005-03-23 | 2009-03-27 | Пфайзер Продактс Инк. (Us) | Комбинированная терапия с использованием анти-ctla4-антитела и индолинона для лечения рака |
BRPI0609957A2 (pt) * | 2005-05-12 | 2010-05-11 | Pfizer | uso de malato de sunitinib na preparação de um medicamento para o tratamento de cáncer |
JP5066446B2 (ja) * | 2005-08-01 | 2012-11-07 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 血管新生阻害物質の効果を予測する方法 |
EP2281901B1 (en) | 2005-08-02 | 2013-11-27 | Eisai R&D Management Co., Ltd. | Anti-tumour pharmaceutical composition with angiogenesis inhibitors |
EP1938842A4 (en) * | 2005-09-01 | 2013-01-09 | Eisai R&D Man Co Ltd | METHOD FOR PRODUCING A PHARMACEUTICAL COMPOSITION COMPRISING IMPROVED CRASHING CHARACTERISTICS |
JP5238504B2 (ja) * | 2005-09-15 | 2013-07-17 | カウンシル・オブ・サイエンティフィック・アンド・インダストリアル・リサーチ | イミダゾリル基で置換された新規なステロイド誘導体およびインダン−1−オン誘導体 |
US20090012085A1 (en) * | 2005-09-20 | 2009-01-08 | Charles Michael Baum | Dosage forms and methods of treatment using a tyrosine kinase inhibitor |
US20090053236A1 (en) * | 2005-11-07 | 2009-02-26 | Eisai R & D Management Co., Ltd. | USE OF COMBINATION OF ANTI-ANGIOGENIC SUBSTANCE AND c-kit KINASE INHIBITOR |
WO2007061127A1 (ja) * | 2005-11-22 | 2007-05-31 | Eisai R & D Management Co., Ltd. | 多発性骨髄腫に対する抗腫瘍剤 |
US20090209580A1 (en) * | 2006-05-18 | 2009-08-20 | Eisai R & D Management Co., Ltd. | Antitumor agent for thyroid cancer |
DE102006024834B4 (de) * | 2006-05-24 | 2010-07-01 | Schebo Biotech Ag | Neue Indol-Pyrrol-Derivate und deren Verwendungen |
US20090203693A1 (en) * | 2006-06-29 | 2009-08-13 | Eisai R & D Management Co., Ltd. | Therapeutic agent for liver fibrosis |
CN1899616A (zh) * | 2006-07-20 | 2007-01-24 | 中国人民解放军军事医学科学院生物工程研究所 | 非受体酪氨酸激酶c-Abl特异性抑制剂的新用途 |
EP2065372B1 (en) | 2006-08-28 | 2012-11-28 | Eisai R&D Management Co., Ltd. | Antitumor agent for undifferentiated gastric cancer |
KR101445892B1 (ko) | 2007-01-29 | 2014-09-29 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 미분화형 위암 치료용 조성물 |
US20090004213A1 (en) * | 2007-03-26 | 2009-01-01 | Immatics Biotechnologies Gmbh | Combination therapy using active immunotherapy |
JP5638244B2 (ja) | 2007-11-09 | 2014-12-10 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 血管新生阻害物質と抗腫瘍性白金錯体との併用 |
JP2011510079A (ja) * | 2008-01-22 | 2011-03-31 | コンサート ファーマシューティカルズ インコーポレイテッド | ゲフィチニブ誘導体 |
JP5399926B2 (ja) * | 2008-01-29 | 2014-01-29 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 血管阻害物質とタキサンとの併用 |
WO2010001167A2 (en) * | 2008-07-02 | 2010-01-07 | Generics [Uk] Limited | Novel process |
US20100143295A1 (en) * | 2008-12-05 | 2010-06-10 | Auspex Pharmaceuticals, Inc. | Quinazoline inhibitors of egfr tyrosine kinase |
US9012458B2 (en) | 2010-06-25 | 2015-04-21 | Eisai R&D Management Co., Ltd. | Antitumor agent using compounds having kinase inhibitory effect in combination |
WO2012042421A1 (en) | 2010-09-29 | 2012-04-05 | Pfizer Inc. | Method of treating abnormal cell growth |
US8962650B2 (en) | 2011-04-18 | 2015-02-24 | Eisai R&D Management Co., Ltd. | Therapeutic agent for tumor |
US9945862B2 (en) | 2011-06-03 | 2018-04-17 | Eisai R&D Management Co., Ltd. | Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds |
CN103127096B (zh) * | 2011-12-02 | 2015-11-25 | 杨子娇 | 吡咯基取代的吲哚类化合物在治疗青光眼病的应用 |
WO2013152193A2 (en) * | 2012-04-04 | 2013-10-10 | Beth Israel Deaconess Medical Center, Inc. | Methods of treating proliferative disorders with malate or derivatives thereof |
JPWO2014098176A1 (ja) | 2012-12-21 | 2017-01-12 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | キノリン誘導体のアモルファス及びその製造方法 |
US10517861B2 (en) | 2013-05-14 | 2019-12-31 | Eisai R&D Management Co., Ltd. | Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds |
KR102329681B1 (ko) | 2014-08-28 | 2021-11-23 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 고순도의 퀴놀린 유도체 및 이를 제조하는 방법 |
DK3263106T3 (da) | 2015-02-25 | 2024-01-08 | Eisai R&D Man Co Ltd | Fremgangsmåde til undertrykkelse af bitterhed af quinolinderivat |
WO2016140717A1 (en) | 2015-03-04 | 2016-09-09 | Merck Sharp & Dohme Corp. | Combination of a pd-1 antagonist and a vegfr/fgfr/ret tyrosine kinase inhibitor for treating cancer |
JP6757959B2 (ja) | 2015-06-16 | 2020-09-23 | 株式会社 PRISM BioLab | 抗がん剤 |
JP7140347B2 (ja) * | 2016-06-09 | 2022-09-21 | 有機合成薬品工業株式会社 | 4-(ピペリジン-4-イル)モルホリンの製造方法 |
AU2020354787A1 (en) * | 2019-09-26 | 2022-04-14 | Starpharma Pty Ltd | Therapeutic dendrimer |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL139934A (en) * | 1998-05-29 | 2007-10-31 | Sugen Inc | History 2 - Indulinone converted to pyrrole and pharmaceutical preparations containing them |
ATE514676T1 (de) * | 1999-11-24 | 2011-07-15 | Sugen Inc | Ionisierbare indolinon derivate und deren verwendung als ptk liganden |
JP5004392B2 (ja) * | 1999-12-22 | 2012-08-22 | スージェン, インク. | インドリノン化合物を用いてc−kitチロシン蛋白質キナーゼ機能を調節する方法 |
MY130363A (en) * | 2000-02-15 | 2007-06-29 | Sugen Inc | "pyrrole substituted 2-indolinone protein kinase inhibitors" |
MY128450A (en) * | 2000-05-24 | 2007-02-28 | Upjohn Co | 1-(pyrrolidin-1-ylmethyl)-3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives |
AR042586A1 (es) * | 2001-02-15 | 2005-06-29 | Sugen Inc | 3-(4-amidopirrol-2-ilmetiliden)-2-indolinona como inhibidores de la protein quinasa; sus composiciones farmaceuticas; un metodo para la modulacion de la actividad catalitica de la proteinquinasa; un metodo para tratar o prevenir una afeccion relacionada con la proteinquinasa |
US6797725B2 (en) * | 2001-04-09 | 2004-09-28 | Sugen, Inc. | Prodrugs of a 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives |
-
2003
- 2003-11-13 AR ARP030104194A patent/AR042042A1/es unknown
- 2003-11-14 NL NL1024779A patent/NL1024779C2/nl not_active IP Right Cessation
- 2003-11-14 TW TW092132030A patent/TW200418837A/zh unknown
- 2003-11-14 EP EP03783527A patent/EP1562600A4/en not_active Withdrawn
- 2003-11-14 CN CNA2008100814220A patent/CN101259131A/zh active Pending
- 2003-11-14 KR KR1020057008541A patent/KR20050086594A/ko not_active Application Discontinuation
- 2003-11-14 JP JP2004553729A patent/JP2006508981A/ja not_active Withdrawn
- 2003-11-14 BR BR0315630-3A patent/BR0315630A/pt not_active IP Right Cessation
- 2003-11-14 UY UY28081A patent/UY28081A1/es not_active Application Discontinuation
- 2003-11-14 WO PCT/US2003/036526 patent/WO2004045523A2/en active Application Filing
- 2003-11-14 CN CNB200380103225XA patent/CN100430060C/zh not_active Expired - Fee Related
- 2003-11-14 MX MXPA05005150A patent/MXPA05005150A/es unknown
- 2003-11-14 CA CA002506308A patent/CA2506308A1/en not_active Abandoned
- 2003-11-14 PL PL376954A patent/PL376954A1/pl not_active Application Discontinuation
- 2003-11-14 RU RU2005118417/14A patent/RU2342140C2/ru not_active IP Right Cessation
- 2003-11-14 US US10/712,296 patent/US20040152759A1/en not_active Abandoned
- 2003-11-14 AU AU2003290943A patent/AU2003290943A1/en not_active Abandoned
- 2003-11-14 PE PE2003001154A patent/PE20040835A1/es not_active Application Discontinuation
- 2003-11-14 PA PA20038588601A patent/PA8588601A1/es unknown
- 2003-11-14 GT GT200300245A patent/GT200300245A/es unknown
-
2005
- 2005-05-11 CO CO05045078A patent/CO5700778A2/es not_active Application Discontinuation
- 2005-05-12 ZA ZA200503841A patent/ZA200503841B/en unknown
- 2005-05-27 NO NO20052578A patent/NO20052578L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
BR0315630A (pt) | 2005-08-23 |
KR20050086594A (ko) | 2005-08-30 |
NO20052578L (no) | 2005-05-27 |
RU2342140C2 (ru) | 2008-12-27 |
CN101259131A (zh) | 2008-09-10 |
EP1562600A4 (en) | 2008-06-25 |
NL1024779A1 (nl) | 2004-05-18 |
AU2003290943A1 (en) | 2004-06-15 |
WO2004045523A2 (en) | 2004-06-03 |
RU2005118417A (ru) | 2006-01-20 |
PE20040835A1 (es) | 2004-11-18 |
PL376954A1 (pl) | 2006-01-09 |
ZA200503841B (en) | 2006-09-27 |
WO2004045523A3 (en) | 2004-09-30 |
GT200300245A (es) | 2004-06-23 |
CN1711089A (zh) | 2005-12-21 |
CO5700778A2 (es) | 2006-11-30 |
EP1562600A2 (en) | 2005-08-17 |
CA2506308A1 (en) | 2004-06-03 |
UY28081A1 (es) | 2004-06-30 |
US20040152759A1 (en) | 2004-08-05 |
NL1024779C2 (nl) | 2004-11-09 |
CN100430060C (zh) | 2008-11-05 |
MXPA05005150A (es) | 2005-07-22 |
PA8588601A1 (es) | 2004-05-21 |
TW200418837A (en) | 2004-10-01 |
JP2006508981A (ja) | 2006-03-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR042042A1 (es) | Administracion combinada de una indolinona con un agente quimioterapeutico para trastornos de proliferacion celular | |
ES2524966T3 (es) | Derivados de tieno[3,2-c]piridina como inhibidores de quinasas para uso en el tratamiento del cáncer | |
PE20191613A1 (es) | Compuestos de pirazolo[1,5-a]piridina sustituidos como inhibidores de la quinasa ret | |
PE20170003A1 (es) | Compuestos heterociclicos y usos de los mismos | |
AR063099A1 (es) | Compuestos y composiciones como inhibidores de la proteina quinasa | |
AR064608A1 (es) | Derivados de pirazolo-quinazolina sustituidos, composiciones farmaceuticas que los contienen. proceso para su preparacion y uso de los mismos como agentes anticancer. | |
PE20121815A1 (es) | Compuestos de pirrolo-pirimidina como inhibidores de cdk4/6 | |
AR047531A1 (es) | Derivados 1h-tieno(2,3-c)pirazol utiles como inhibidores de quinasa | |
AR097431A1 (es) | Compuestos de carboxamida de furo y tienopiridina útiles como inhibidores de quinasas pim | |
ECSP105253A (es) | Derivados de 5-feniltiazol y uso como inhibidores de pi3 cinasa | |
MX2013005445A (es) | Pirazolopiridinas y el uso de pirazolopiridinas como inhibidores de tirosina cinasa 2 (tyk2). | |
CO6251254A2 (es) | Uso de inhibidores de piridopirimidinona de pi3k en el tratamiento del cancer | |
AR053364A1 (es) | Compuesto de 1h-imidazo 84,5-c) piridin -2- ilo, composicion farmaceutica que lo comprende, proceso para prepararla y su uso para preparar un medicamento para tratamiento de cancer o artritis | |
SV2018005655A (es) | "derivados de 8-[6-[3-(amino)propoxi]-3-piridil]1-isopropilimidazo[4,5-c]quinolin-2-ona como moduladores selectivos de la cinasa de la ataxia telangiectasia mutada (atm) para el tratamiento del cancer" | |
CL2009001152A1 (es) | Compuestos derivados de n-(4-(cicloalquilo nitrogenado-1-il)-1h-pirrolo[2,3-b]piridin-3-il)amida, inhibidores de cinasa; proceso de preparacion; composicion farmaceutica; y su uso para el tratamiento de una enfermedad proliferativa. | |
AR041184A1 (es) | Derivados de benzopiranonas, inhibidores de las cinasas dependientes de ciclinas y su uso | |
AR087288A1 (es) | Compuestos de tetrahidropirido-piridina y tetrahidropirido-pirimidina y su uso como moduladores de receptores de c5a | |
EA200900593A1 (ru) | Производные птеридина как ингибиторы polo-подобной киназы, применяющиеся при лечении рака | |
ECSP10010585A (es) | Compuestos de 2- imido- 3- metil pirrolo pirimidinona fenilo- sustituidos como inhibidores bace- 1, composiciones, y su uso | |
HUP0303271A2 (hu) | Rapamycin felhasználása rák kezelésére alkalmas gyógyszerkészítmény elõállítására | |
PE20080928A1 (es) | Derivados de anilinopiperazina como inhibidores de proteina quinasa | |
PE20130306A1 (es) | Morfolinopirimidinas y su uso en terapia | |
PE20121506A1 (es) | Compuestos triazolopiridinas como inhibidores de c-met | |
PE20070832A1 (es) | Derivados de piridazinona como inhibidores de la tirosina quinasa | |
AR047098A1 (es) | Derivados de arilanilina como agonistas del receptor adrenergico beta2 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |